Pfizer (PFE.US) eases profit pressure: Strong demand for existing drug portfolio in Q2 drives 2026 revenue guidance up, adds $2.5 billion in cost reductions.

Zhitong Finance APP learned that on Tuesday before the U.S. stock market opened, Pfizer (PFE.US) announced its financial report for the second quarter of 2026. Against the backdrop of declining revenue from COVID-19 products, the company achieved better-than-expected revenue growth driven by strong performances from core non-COVID products such as Eliquis and Padcev, and raised the lower limit of its annual revenue guidance. However, a $4.3 billion non-cash impairment of intangible assets dragged down the GAAP net loss, and the stock price increased by about 0.52% to $25.16 in pre-market trading.